| 6.39 -0.05 (-0.78%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 7.87 | 1-year : | 9.19 |
| Resists | First : | 6.73 | Second : | 7.87 |
| Pivot price | 5.68 |
|||
| Supports | First : | 5.35 | Second : | 4.5 |
| MAs | MA(5) : | 6.13 |
MA(20) : | 5.83 |
| MA(100) : | 5.22 |
MA(250) : | 3.7 |
|
| MACD | MACD : | 0 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 90.7 |
D(3) : | 80.7 |
| RSI | RSI(14): 58.8  |
|||
| 52-week | High : | 8.19 | Low : | 1.57 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ HOWL ] has closed below upper band by 12.4%. Bollinger Bands are 4.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.66 - 6.69 | 6.69 - 6.71 |
| Low: | 6.18 - 6.23 | 6.23 - 6.25 |
| Close: | 6.33 - 6.39 | 6.39 - 6.44 |
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Wed, 24 Apr 2024
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society ... - Yahoo Finance Australia
Mon, 15 Apr 2024
All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy - Yahoo Finance
Mon, 15 Apr 2024
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Update - MarketBeat
Wed, 10 Apr 2024
Werewolf Therapeutics Enters Oversold Territory (HOWL) - Nasdaq
Tue, 09 Apr 2024
Institutional investors in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) see US$43m decrease in market cap last week ... - Simply Wall St
Thu, 04 Apr 2024
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology ... - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 6.6 (%) |
| Held by Institutions | 72.9 (%) |
| Shares Short | 472 (K) |
| Shares Short P.Month | 465 (K) |
| EPS | -1.05 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.84 |
| Profit Margin | -187.4 % |
| Operating Margin | -863.6 % |
| Return on Assets (ttm) | -15.2 % |
| Return on Equity (ttm) | -32 % |
| Qtrly Rev. Growth | -79.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.45 |
| EBITDA (p.s.) | -0.9 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -6.09 |
| PEG Ratio | -1.2 |
| Price to Book value | 2.24 |
| Price to Sales | 13.89 |
| Price to Cash Flow | -8.5 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|